301 related articles for article (PubMed ID: 22336881)
1. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
Paller CJ; Antonarakis ES
Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
[TBL] [Abstract][Full Text] [Related]
2. Pharmaco-economic aspects of sipuleucel-T.
Simoens S
Hum Vaccin Immunother; 2012 Apr; 8(4):506-8. PubMed ID: 22336882
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
4. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.
Wesley JD; Whitmore J; Trager J; Sheikh N
Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520
[TBL] [Abstract][Full Text] [Related]
5. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.
Gaines KK
Urol Nurs; 2012; 32(2):95-8. PubMed ID: 22690466
[No Abstract] [Full Text] [Related]
6. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
Patel PH; Kockler DR
Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
[TBL] [Abstract][Full Text] [Related]
7. Two years of Provenge.
Riedmann EM
Hum Vaccin Immunother; 2012 Apr; 8(4):505. PubMed ID: 22832253
[No Abstract] [Full Text] [Related]
8. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
10. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
11. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Nabhan C
N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391
[No Abstract] [Full Text] [Related]
13. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
14. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
Holko P; Kawalec P
Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
[TBL] [Abstract][Full Text] [Related]
17. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
Madan RA; Aragon-Ching JB; Gulley JL; Dahut WL
Expert Rev Vaccines; 2011 Jun; 10(6):743-53. PubMed ID: 21692697
[TBL] [Abstract][Full Text] [Related]
18. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
19. Integration of immunotherapy into the management of advanced prostate cancer.
Kantoff P; Higano CS
Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
[TBL] [Abstract][Full Text] [Related]
20. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]